Dong-A Pharmaceutical Subsidiary Dong-A ST Wins South Korean Approval for Once-Daily Gastritis Drug

Bitget2026/11/01 22:45

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Dong-A Pharmaceutical subsidiary Dong-A ST received South Korean regulatory approval for gastritis treatment Stillen Q on Oct. 30, 2026.
The treatment reduces dosing to once daily, compared with three times daily for Stillen and twice daily for Stillen 2X.
A domestic launch remains subject to a review of market conditions and commercial viability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dong-A Pharmaceutical Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261102800007), on November 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Dong-A Pharmaceutical Subsidiary Dong-A ST Wins South Korean Approval for Once-Daily Gastritis Drug

You may also like

Crypto prices